Engineers at MIT say they developed a flexible drug delivery patch for promoting healing and tissue regeneration after heart attacks. The patch, placed on the heart after a heart attack, can help both heal and regenerate cardiac tissue. MIT said its engineers designed the patch to carry several different drugs capable of release at different […]
Cardiovascular
Orchestra BioMed, Terumo terminate drug-eluting balloon distro deal in $30M agreement
Orchestra BioMed (Nasdaq:OBIO) announced today that it entered into a termination and right of first refusal agreement with Terumo. The agreement relates to the New Hope, Pennsylvania-based company’s Virtue Sirolimus AngioInfusion Balloon (SAB). It supersedes and terminates a prior distribution agreement between the companies and grants Terumo a right of first refusal (ROFR) to acquire […]
Boston Scientific shares positive Agent drug-coated balloon findings
Boston Scientific (NYSE: BSX) today shared findings from new analyses of its Agent drug-coated balloon (DCB). Agent serves as an alternative to traditional therapies like balloon angioplasty, additional layers of stenting or radiation. The paclitaxel-coated balloon transfers a therapeutic dose of drug to the vessel wall, helping to prevent in-stent restenosis (ISR) reoccurrence. The FDA […]
Orchestra BioMed enrolls first patient in Sirolumus AngioInfusion balloon trial
Orchestra BioMed (Nasdaq:OBIO) today announced the first patient enrollments in a study of its Virtue Sirolimus AngioInfusion Balloon (SAB). The FDA investigational device exemption (IDE) trial compares the Virtue SAB to the Boston Scientific Agent paclitaxel-coated balloon. Agent is currently the only FDA-approved drug-coated balloon (DCB) for coronary indication, picking up approval in March. New Hope, […]
Teleflex enrolls first patient in dual-drug-eluting device study of coronary interventions for diabetes
Teleflex (NYSE:TFX) announced today that it enrolled the first patient in its DUBSTENT DIABETES trial. The randomized, investigator-initiated trial evaluates a dual-device strategy for percutaneous coronary intervention (PCI) in patients with diabetes mellitus. DUBSTENT DIABETES investigates the safety and efficacy of combining drug-coated balloon (DCB) angioplasty with drug-eluting stent (DES) implantation compared to single-device strategies […]
Abbott wins CE mark for Esprit drug-eluting, dissolving scaffold
Abbott (NYSE: ABT) announced today that it received CE mark for its Esprit BTK everolimus-eluting resorbable scaffold system. Esprit BTK offers treatment for people with peripheral artery disease (PAD) below the knee (BTK). Abbott designed it to keep arteries open and deliver the drug everolimus to support vessel healing. Following the therapy, the stent completely […]
Boston Scientific launches head-to-head drug-coated balloon trial
Boston Scientific (NYSE:BSX) announced today that it initiated a new trial to assess its Agent DCB compared to the standard of care. The AGENT DCB STANCE trial pits the drug-coated balloon (DCB) head-to-head against percutaneous coronary intervention (PCI) treatment with drug-eluting stents (DES) and/or balloon angioplasty – in patients with de novo (previously untreated) coronary […]
Boston Scientific earns Medicare reimbursement for Agent drug-coated balloon
Boston Scientific (NYSE: BSX) announced today that CMS granted reimbursement for its Agent drug-coated balloon (DCB). CMS granted a new technology add-on payment (NTAP) for eligible cases using Agent. NTAP provides additional reimbursement to hospitals that use designated new medical technologies in the first few years of market introduction. Starting Oct. 1, 2025, CMS intends […]
Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
Elixir Medical announced three-year results from a large randomized controlled trial of its DynamX coronary bioadaptor system. The 445-patient BIOADAPTOR trial compares DynamX to the standard of care Medtronic Resolute Onyx drug-eluting stent (DES). It took place across 34 centers in Japan, Europe and New Zealand. Data — shared this week at EuroPCR 2025 in […]
Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
Medtronic announced today that it received CE mark for several expanded indications for its Prevail balloon catheter. The expanded indications for the paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA) balloon catheter (or drug-coated balloon/DCB) cover the treatment of coronary artery disease (CAD). According to the medtech giant, Prevail now has the broadest range of CE mark […]
